Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab.
The use of induction therapy may reduce the risk of acute rejection after heart transplantation. This study assessed the association between basiliximab (BAS) vs anti-thymocyte globulin (ATG) induction and long-term survival after heart transplantation.